Jack Pace is a core member of White & Case's leading global antitrust litigation practice, which is ranked by Chambers USA in Band 1 and Legal 500 in Tier 1 for cartel matters and civil litigation/class actions, respectively, and has won the Competition Group of the Year award from Law360 more than any other firm has, an unprecedented seven times. The Firm's antitrust practice has been named as one of the Global Competition Review's "Global Elite" and is ranked in the top 3 of that publication's "GCR 100" rankings.
Drawing upon energy and creativity well known to the Firm's clients, Jack has achieved major victories in many complex litigation matters, including jury verdicts (in antitrust, unfair competition, and RICO cases), appellate victories (Asacol antitrust litigation, Doryx antitrust litigation, GM seeds antitrust litigation), dismissals of antitrust claims on the pleadings and at summary judgment (January 2021 "short squeeze"/"meme stock" litigation, numerous "reverse payment" and "product hopping" cases, Black v. JP Morgan Chase, VantageScore antitrust litigation, auto repair consumer protection litigation), and groundbreaking defeats of class certification (Asacol antitrust litigation, GM seeds antitrust litigation, court reporting unfair competition litigation).
Jack successfully has represented clients in numerous trials, arbitrations and other litigation settings against private parties, federal prosecutors, and state attorneys general. He also has represented many leading global companies in litigation at the cutting edge of antitrust and intellectual property law.
Jack has been recognized as a leading litigator and antitrust lawyer by several publications. Jack is ranked in Chambers (where clients reported that "Jack excels in public speaking and court performance" and "is responsive, strategic and sees the big picture"), in Legal 500 US as a Leading Lawyer in the Civil Litigation/Class Actions category, and in Who's Who Legal as a Future Leader in the Competition category (where clients described Jack as a "great strategist"). Jack is also a two-time "MVP" in Law360, winning the award in the Life Sciences category 2015 and in the Competition category in 2011. Jack also was named a "Rising Star under age 40" among US competition lawyers by Law360 in 2013 and a "Rising Star" among all lawyers in New York City by the New York Law Journal in 2013.
Jack works with clients across a broad spectrum of industries, including technology, pharmaceuticals, financial services, fintech, agriculture, energy, and sports leagues.
Jack has served in a variety of leadership roles at the firm, including most recently as Head of the Competition Section for the Firm's Americas Region (2018–2022) and Executive Partner of the Firm's New York Office (2013–2018).
In addition to his client practice, Jack serves as Practice Leader of the Firm's leading Global Pro Bono Practice. He has done extensive work on behalf of the Firm's pro bono clients, in cases involving domestic violence, criminal appeals, and special education. He also serves on the Board of Directors of Reach Out and Read of Greater New York, a not-for-profit organization focused on school readiness and early literacy.
Jack is an associate editor of Antitrust Magazine and regularly publishes articles on antitrust law, class certification, and other subjects.
Litigation regarding collaborations
Successfully has represented clients in litigation and government investigations into joint ventures and other collaborations in the financial services, pharmaceutical, medical technology, and sports industries.
Successfully defended Boston Scientific Corporation in antitrust and False Claims Act litigation regarding challenges to licensing and marketing agreements relating to the sale of prostate cancer treatments.
Regularly counsels clients on the formation of research and marketing collaborations, joint ventures, and startups.
Represented a coalition of economists and university professors submitting an amicus brief on the proper application of the antitrust laws in the United States Supreme Court appeal regarding compensation for NCAA student-athletes.
Litigation regarding innovation
Successfully defended Allergan in nationwide antitrust class action litigation regarding the company's leading Botox® Cosmetic product. The plaintiffs sought to prevent competition by blocking an exclusive license agreement that would create new competition in the sale of injectable neurotoxins in the United States.
Successfully defended several leading pharmaceutical and medical device manufacturers against antitrust challenges to the prosecution and enforcement of intellectual property rights.
Successfully defended several leading manufacturers against antitrust challenges to the launch of new products.
In a noteworthy example, represented Allergan/Warner Chilcott in litigation brought by competitor Mylan, challenging Warner Chilcott's transition to new versions of its Doryx acne treatment. Jack and the White & Case team obtained dismissal of all of Plaintiff's claims on summary judgment, representing the first-ever victory for a defendant on a full evidentiary record in a so-called pharmaceutical "product hopping" litigation. The Third Circuit Court Appeals affirmed the client's victory, creating the first appellate precedent in favor of a defendant in a "product hopping" case.
Successfully defended Apex Clearing Corporation in antitrust, securities law, and common law tort challenges relating to so-called "short squeeze" efforts by traders of meme stocks. The District Court for the Southern District of Florida dismissed all claims against Apex with prejudice.
Successfully represented fintech firms in FINRA and other arbitrations regarding securities trading, clearing firm operations, and credit scoring services.
Advising various financial services, fintech, and private equity firms on antitrust compliance, joint ventures, and new service offerings.
Class action defense
Successfully represented defendants from a variety of industries facing class actions and achieved precedent-setting victories in defeating class certification, including in the Asacol Antitrust Litigation (1st Circuit), the GM Seeds Antitrust Litigation (8th Circuit), and the Loestrin Indirect Purchaser Antitrust Litigation (1st Circuit).
Antitrust challenges to pharmaceutical settlement agreements and IP enforcement
National trial counsel for several leading pharmaceutical manufacturers (including AbbVie, Boehringer Ingelheim, Boston Scientific, Hikma, and Pfizer) in antitrust challenges to settlement agreements and efforts to enforce intellectual property rights. Among other things, Jack has played a leading role in the class certification and economic analyses involved in these cases.
Consolidated price-fixing class actions
Successfully defended a leading global potash supplier in consolidated class action litigation involving claims under antitrust and unfair competition laws.
Successfully defended clients in a variety of sectors, including information services, health care, commodities, and automotive manufacturing in antitrust lawsuits challenging joint conduct under the antitrust laws.
FDA regulatory approval of innovative pharmaceutical products
Successfully defended a leading global pharmaceutical manufacturer in preliminary injunction proceedings that challenged Food and Drug Administration (FDA) approval of a biosimilar drug.
Credit data antitrust, consumer protection, and trademark litigation
Representing Experian, Jack and his colleagues obtained a jury verdict on all claims brought by Fair Isaac Corporation in an action concerning allegations of unfair competition and trademark infringement in the sale of credit risk scoring services. The jury also found in favor of Experian on its counterclaim that the plaintiff had committed fraud on the US Patent and Trademark Office in obtaining its registration for the trademark-in-suit. Jack and his colleagues also obtained dismissal of all antitrust and false advertising claims on summary judgment. The trial victory and summary judgment victory were upheld by the 8th Circuit Court of Appeals.
In a separate case brought by a proposed nationwide class of purchasers, Jack and his colleagues obtained dismissal of all claims asserting antitrust violations against Experian and various leading financial institutions.
Antitrust / intellectual property litigation
Successfully represented several major pharmaceutical manufacturers in monopolization litigation involving allegations of fraud on the United States Patent and Trademark Office and sham litigation.
Defense against deceptive and unfair trade practice claims
Represented a legal services support company in class action litigation asserting claims under state deceptive and unfair trade practice laws. Jack and his colleagues obtained denial of the class certification motion and dismissal of all claims against our client.
Employment class action litigation
Represented a leading pharmaceutical company in putative class actions involving claims under Title VII and the wage and hour laws, respectively. Obtained the dismissal of all claims against our clients in both matters on grounds of corporate separateness and plaintiffs' failure to justify piercing the corporate veil.
Represented a coalition of insurance companies in a 10-week jury trial involving RICO and fraud claims. Member of the trial team that obtained the first jury verdict against the tobacco companies by a third-party payer.
"10 Minutes of Antitrust: Private Equity in the Spotlight of US Antitrust Authorities," Video, www.whitecase.com, May 25, 2023
"Antitrust and Private Equity in the Biden Administration," 10th Bill Kovacic Antitrust Salon, Concurrences and George Washington University Law School, Sept. 12, 2022
"Class Actions: An Emerging Global Divergence?," 48th Annual Conference on International Antitrust Law & Policy, Fordham Competition Law Institute, Oct. 1, 2021
"The Future of Antitrust Case Law: What the Courts Could Say About the New Trends," 9th Bill Kovacic Antitrust Salon, Concurrences and George Washington University Law School, Sept. 28, 2021
"The Supreme Court's NCAA Decision and Its Implications for Antitrust Law," Video, www.whitecase.com, Sept. 2, 2021
"Product Hopping in the COVID-19 Era," The Road to "Business As Usual" in America's Pharmaceutical Industry, Webinar, June 25, 2020
Guest Lecturer, "Antitrust Law," Fordham University School of Law, 2009, 2010, 2012, and 2020
"Is Antitrust the Miracle Cure for Drug Prices?," The 38th NERA Antitrust and Trade Regulation Seminar, July 5, 2019
"Pricing Issues In Pharma: Pay-For-Delay, Product Hopping . . . .," The Global Antitrust Economics Conference, Concurrences/NYU Stern School of Business, May 31, 2019
"The Interplay of IP and Antitrust: What You Should Know in 2019," Webinar, April 3, 2019
American Lawyer Podcast, "The Modern Law Office: Can You Handle It?," January 11, 2019
"Global Antitrust Pharma Webinar: Transatlantic Perspectives on Market Definition," May 23, 2018
"Global Antitrust Pharma Webinar: A Transatlantic Perspective on Product Hopping and Excessive Pricing," Nov. 30, 2017
"Recent Antitrust Developments: June, July and August 2013", ABA Section of Antitrust Law, Health Care and Pharmaceuticals Committee, September 13, 2013
"Class Actions in Federal Court after Shady Grove", sponsored by Strafford Publications Inc., July 14, 2011
"U.S. Supreme Court's Decision in AT&T Mobility, LLC v. Concepcion," Bloomberg Radio, April 28, 2011
Keynote speaker, Volunteer Lawyers for Justice (on private law firm support for public interest legal work), April 8, 2009
"Hot Topics in E-Discovery: Attorney-Client Privilege, New FRE 502, and Spoliation Sanctions," Bloomberg Litigation Seminar, June 5, 2008
"Managing Second Requests: Electronic Discovery," Antitrust Practicum Brown Bag Series, ABA Section of Antitrust Law and Young Lawyers Division Antitrust Committee, February 27, 2008
"Global Cartel Investigations and Recent Antitrust Law Developments: Japan, the EU, the US, and China," Japan Machinery Center for Trade and Investment, September 13, 2007
"Global Cartel Investigations and Recent Antitrust Law Developments: Japan, the EU, the US, and China," White & Case Tokyo Special Invitation Seminar, September 12, 2007
"Is It Game Over for PlayStation Store Antitrust Suit?," White & Case Technology Newsflash (Aug. 8, 2022) (co-author)
"Sweeping US Order on 'Promoting Competition'" White & Case Client Alert (July 12, 2021) (co-author)
"What's next for drug pricing in the US?," White & Case Client Alert (June 8, 2021) (co-author)
A Moment of Clarity in the IBOR Transition: DOJ Antitrust Division Issues Business Review Letter Approving ISDA's Proposed Protocol for Derivatives," White & Case Client Alert (Oct. 6, 2020)
"Understanding and Un-Tying Product Hopping Litigation, Part II: A Reply to Carrier and Shadowen," Antitrust, Vol. 33, No. 2, Spring 2019 (co-author)
"Doryx, Namenda, and Coercion: Understanding and Un-Tying Product-Hopping Litigation," Antitrust, Vol. 32, No. 3, Summer 2018 (co-author)
"Looking for Sunlight in Shady Grove: The Fate of State Law in Federal Diversity Cases Remains Unclear," Antitrust, Volume 30, No. 2, Spring 2016 (co-author)
"Third Circuit Holds, 'Give Peace a Chance': The De Beers Litigation and the Potential Power of Settlement," Antitrust, Volume 27, No. 2, Spring 2013 (co-author)
"E-discovery 'Worst Practices,'" 4 The Senior Lawyer 56, Spring 2012 (co-author)
Antitrust Law Developments (Seventh), 2012 (contributor to chapter on equitable and class action tolling)
The Monopolization and Dominance Handbook, American Bar Association, Antitrust Section, July 2011 (contributing editor)
"From Shady to Dark: One Year Later, Shady Grove's Meaning Remains Unclear," Antitrust, Volume 25, No. 2, Spring 2011 (co-author)
"E-discovery 'Worst Practices': Ten Sure-Fire Ways to Mismanage Document Review and Production," 14 N.Y. Bus. L.J. 62, Winter 2010 (co-author)
"E-discovery 'Worst Practices,'" 2 The Senior Lawyer 33, Fall 2010 (co-author)
"E-discovery 'Worst Practices': Ten Sure-Fire Ways to Mismanage a Litigation Hold," 13 N.Y. Bus. L.J. 48, Fall 2009 (co-author)
Annual Review of Antitrust Law Developments, 2008 (contributor to chapter on vertical non-price restraints)
"The Recent Wave, or Ripple, of Antitrust Class Certification Denials," Antitrust Practitioner, Volume 5, December 2006 (co-author)
"Testing the Security Blanket: An Analysis of Recent Challenges to Stipulated Blanket Protective Orders," Antitrust, Volume 19, No. 3, Summer 2005
"Conspiratologists at the Gate: The Scope of Expert Testimony on the Subject of Conspiracy in a Sherman Act Case, Antitrust," Volume 17, No. 2, Spring 2003, (co-author)
"Automatic Stays and Governmental Operations: How New York State Protects the Government from the Poor," 24 Fordham Urban Law Journal, Page 137, 1996
Chambers USA (individually ranked), Antitrust, 2021-2022
Legal 500 US, Leading Lawyer in Antitrust Civil Litigation/Class Actions Category, 2020-2022
Who's Who Legal, Competition Future Leader, 2021-2023
MVP, Life Sciences, Law360, 2015
Co-MVP, Antitrust Litigation – Competition, Law 360, 2011
Lawdragon, Named to 500 Leading Litigators in Americas, 2022
Appointed as Fellow to American Bar Foundation, 2017
Benchmark Litigation, "Litigation Star" 2017-2020
New York State Bar Association Class Action and Private Litigation Committee, 2020-2023
New York State Bar Association Monopolization and Big Tech Committee, 2021-2023
New York City Bar's Antitrust & Trade Regulation Committee, 2014-2023
Rising Star, US Competition Lawyers aged 40 and under, Law 360, 2013
Rising Star aged 40 and under, New York Law Journal, 2013
Jack Pace was named a "Litigator of the Week" by Global Competition Review for securing reversal of class certification in the Asacol® product-hopping litigation.